Skip to main content
. 2021 May 21;17(1):16–23. doi: 10.1159/000515729

Fig. 2.

Fig. 2

Progression-free survival of subsequent treatments. Group A: exemestane plus everolimus (black line), group B: endocrine monotherapy (red line), group C: chemotherapy (green line). Symbols indicate censored data. The median PFS was 4.0 months in group A, 3.8 months in group B, and 6.6 months in group C. Survival rate was estimated by using the Kaplan-Meier method and compared by using the log-rank test.